Dies ist eine HTML Version eines Anhanges der Informationsfreiheitsanfrage 'The Vaccines Procurement Steering Committee & the Joint Negotiation Team'.


Ref. Ares(2020)2040853 - 14/04/2020
From: 
@gsk.com> 
Sent: 
mardi 14 avril 2020 13:06 
To: 
BUCHER Anne (SANTE); SEYCHELL Martin (SANTE) 
Cc: 
@sanofi.com; 
@sanofi.com; 
@sanofi.com 
Subject: 
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight 
COVID-19 
Attachments: 
Press Release - Sanofi and GSK to join forces in unprecedented vaccine 
collaboration to fight COVID-19 14042020.pdf 
 
Categories: 
A voir par 
 
 
Dear Mrs Bucher and Mr Seychell,
Today, Sanofi and GSK announce we are entering into a collaboration to develop an adjuvanted vaccine 
for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
Definitive terms of the collaboration are expected to be finalised over the next few weeks.  
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. 
GSK will contribute its proven pandemic adjuvant technology to the collaboration. We plan to initiate 
phase I clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, 
aim to complete the development required for licensure
Considering the extraordinary humanitarian and financial challenge of the pandemic, both companies 
believe that global access to COVID-19 vaccines is a priority and are committed to making any vaccine 
that is developed through the collaboration affordable to the public and through mechanisms that offer fair 
access for people in all countries.  
It is clear no one company can address COVID-19 alone and we are proud that this collaboration brings 
together two of the world’s largest vaccines companies.  
The press release announcing this news is attached; please feel free to reach out if you have any 
questions. 

GSK: 
@gsk.com 

Sanofi Pasteur: 
@sanofi.com 
We have also informed President von der Leyen and Commissioners Kyriakides, Breton, Gabriel and 
Lenarþiþ.
Best wishes, 
 
 
 
 
Communications and Government Affairs, Vaccines 
GSK 
20, Avenue Fleming, Building W23, 1300 Wavre, Belgium
Email:  
@gsk.com
Mobile:  
     Tel (landline):  
 


 
gsk.com  |  Twitter  |  YouTube  |  Facebook  |  Flickr
 
 
 
 
  
GSK monitors email communications sent to and from GSK in order to protect GSK, our 
employees, customers, suppliers and business partners, from cyber threats and loss of GSK 
Information. GSK monitoring is conducted with appropriate confidentiality controls and in 
accordance with local laws and after appropriate consultation.